Meeting
2018 ASCO Annual Meeting
Carboplatin (CBDCA), S-1 and concurrent thoracic radiotherapy (TRT) for elderly patients with locally advanced non-small cell lung cancer (NSCLC): A phase II study.
Authors
Seiji Niho
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Seiji Niho , Shigeki Umemura , Yukio Hosomi , Hiroaki Okamoto , Keiji Nihei , Hiroshi Tanaka , Toyoaki Hida , Koichi Goto , Tetsuo Akimoto , Yuichiro Ohe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
UMIN000005794
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8530)
DOI
10.1200/JCO.2018.36.15_suppl.8530
Abstract #
8530
Poster Bd #
136
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A randomized phase II study of TS-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC): WJOG 5008L.
First Author: Takashi Seto
Poster
2019 ASCO Annual Meeting
Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non–small-cell lung cancer (NSCLC): KEYNOTE-799.
First Author: Salma K. Jabbour
Poster
2017 ASCO Annual Meeting
Randomized trial of thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer (NSCLC): Long-term follow-up of Japan Clinical Oncology Group (JCOG) Study JCOG0301.
First Author: Shinji Atagi
Poster
2017 ASCO Annual Meeting
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (TORG1018).
First Author: Kaoru Kubota